New York, Feb 11, 2026, 15:00 EST — Regular session.
- Medtronic shares dipped in afternoon trading, underperforming the modest gains seen across the broader market.
- Traders are making moves ahead of the company’s quarterly earnings and management update scheduled for next week.
- An analyst upgrade has shifted focus back to Medtronic’s product cycle and recent portfolio changes.
Medtronic plc shares dropped roughly 0.9% to $100.53 Wednesday afternoon, despite the S&P 500 ETF ticking upward. Abbott and Johnson & Johnson saw gains, whereas Boston Scientific declined.
Medtronic’s pullback comes ahead of its fiscal third-quarter results, set for Feb. 17. Investors are watching closely to see if the new product cycle is driving faster growth. The company plans to release earnings around 5:45 a.m. CST and hold a webcast at 7:00 a.m. CST. (Medtronic News)
Needham & Co. has upgraded Medtronic to a “buy,” citing a series of product launches in major markets that could finally boost its organic revenue growth—this metric excludes currency fluctuations and acquisitions. Analyst Mike Matson and his team highlighted Elliott Management’s involvement and fresh board members as catalysts to enhance execution, organic growth, and profitability. They specifically noted new launches like pulsed field ablation for atrial fibrillation, renal denervation for hypertension, Medtronic’s Hugo soft-tissue surgical robot, and the AltaViva tibial nerve stimulation device for urge urinary incontinence. (MassDevice)
Pulsed field ablation treats AFib by delivering electrical pulses instead of relying on heat or freezing to interrupt faulty heart signals. Renal denervation, on the other hand, is a catheter-based method that lowers blood pressure by targeting nerves in the renal arteries.
Analyst price targets remain all over the map. According to Benzinga, Needham set the highest target at $121 on Feb. 9, while the consensus hovers near $106.71. (Benzinga)
Wednesday’s shift highlights just how impatient the market is: Medtronic needs to prove it can handle the daily grind of launches and procedure growth, not merely flaunt a promising pipeline. Investors will be zeroed in on details about adoption rates, pricing, and the sales rhythm within the heart and surgical divisions.
The setup works both ways. If hospitals adopt more slowly, reimbursement stays patchy, or competition heats up, newer categories could take longer to gain traction. That could leave the stock trapped in a familiar cycle: exciting product announcements followed by uneven follow-through.
Medtronic’s report and earnings call on Feb. 17 stands out as the next key event. Investors will be keenly watching for any changes in growth momentum and how the leadership outlines their plans for the rest of fiscal 2026.
